Natreon’s Crominex3+ Receives Patent

138

New Brunswick, NJ—Crominex3+, a Natreon ingredient that according to the company provides cardiovascular health benefits, received a U.S. Patent, according to a press release.

The press release states that Crominex3+ is a composition of trivalent chromium chloride and alma and shilajit extracts that affect the improvement of lipid profile and endothelial function. The new patent and 7 clinical studies on Crominex®3+ institute the ingredient as an optimal product for heart health support, according to the release.

“We are glad that USPTO has granted a well-deserved patent for cardiovascular health benefits of Crominex3+, the most efficacious of several chromium supplements from the market,” Dr. Sanni Raju, CEO of Natreon, said in the release. “Crominex3+ has amazing synergistic activity that showed significant improvement in endothelial function, lipid profile, hsCRP, as well as HbA1c, which are all important factors for cardiovascular health. Synergistic activity of Crominex3+ is achieved by using totally natural materials.”

The addition of this patent marks number 28 in active domestic and international patents for Natreon products.

LEAVE A REPLY

Please enter your comment!
Please enter your name here